Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
Clinical trial data demonstrates that both agents can achieve substantial weight loss, with Retatrutide achieving up to 24% body weight reduction and Cagrilintide reaching over 20% when combined with semaglutide
Shop now Explore Everlywell
The full Z02 family, current for FY2026, is listed below
Serious adverse events are uncommon when doses remain within the prescribed range
Whilst retatrutide targets GLP-1, GIP, and glucagon receptors to reduce appetite and increase energy expenditure, cagrilintide acts via the amylin receptor pathway a distinct hormonal axis
US$ 29.80
US$ 27.15
US$ 21.16
US$ 28.78
US$ 24.37
